Comment on the 'AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137' (Med. Phys. 36, 5310-5322 (2009))

摘要

The recently published report of the AAPM Task Group 137 addresses many important issues in contemporary low dose rate prostate brachytherapy and provides useful guidelines for the brachytherapy community. However, we disagree with the recommendation contained in Sec. IV.F, which states that planning V150 should be limited to <=50% without regard to the isotope employed. The commonly used radionuclides 1-125, Pd-103, and Cs-131 possess significantly different physical characteristics of energy spectrum and half-life, and prostate glands vary in size and shape.